Claims
- 1. A pharmaceutical composition in the form for oral administration in the prevention of inflammation in mammals comprising an effective inflammation-alleviating amount of at least one phospholipid and a non-steroidal inflammation-preventing compound comprising 5-fluor-2-methyl-1-p-(methylsulphenyl)-benzylideneindene-3-acetic acid, said phospholipid and said compound being present in a molar ratio ranging from about 0.1:1 to about 20:1, respectively.
- 2. The composition of claim 1 wherein the inflammation-preventing compound and the at least one phospholipid are present in molar ratios ranging from about 1:0.5 to about 1:2.
- 3. The composition of claim 1 or 2 wherein the at least one phospholipid is phosphatidylcholine.
- 4. The composition of claim 1 or 2 wherein the at least one phospholipid comprises phosphatidylcholine and phosphatidylinositol.
- 5. The composition of claim 1 comprising sulindac and phosphatidylcholine which are present in a molar ratio ranging from about 1:0.2 to about 1:2.
- 6. A method of alleviating inflammation in a mammal comprising orally administering to said mammal an effective inflammation-alleviating amount of a pharmaceutical composition comprising at least one phospholipid and non-steroidal inflammation-preventing compound comprising 5-fluor-2-methyl-1-p-(methylsulphenyl)-benzylidene-indene-3-acetic acid, said phospholipid and said compound being present in a molar ratio ranging from about 0.1:1 to about 20:1, respectively.
- 7. The method of claim 6 wherein the at least one phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylinositol and mixtures thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2856333 |
Sep 1978 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 104,449, filed Dec. 17, 1979.
Divisions (1)
|
Number |
Date |
Country |
Parent |
104449 |
Dec 1979 |
|